ALT Share Price Performance
US$3.16
-1.27 (-28.67%)
79.5% undervalued intrinsic discount
US$15.45
Fair Value
Price US$3.16
AnalystConsensusTarget US$15.45
AnalystHighTarget US$28.00
Fair ValueUS$15.45
Share Pricen/a
Altimmune, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 45 Fair Values set on narratives written by author
ALT Community Narratives
AN
Fair Value
·Fair Value US$15.45 79.5% undervalued intrinsic discount
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value
·Fair Value US$28 88.7% undervalued intrinsic discount
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
A small biotech is pushing a single drug into late-stage testing for serious liver disease, and a near-term study update could reshape how quickly it reaches patients. The big question is whether it can stand out in a crowded field and avoid the delays, funding needs, and trial setbacks that often derail early-stage drug developers.Read more
AN
US$15.45
79.5% undervalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
1.21kx
Price in 2029
US$19.05
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
Catalysts About Altimmune Altimmune is a clinical stage biopharmaceutical company developing pemvidutide, a dual GLP-1 and glucagon agonist targeting MASH, alcohol use disorder and alcohol-associated liver disease. What are the underlying business or industry changes driving this perspective?Read more
AN
US$28
88.7% undervalued intrinsic discount
Fair Value
Profit Margin
16.24%
Future PE
122.49x
Price in 2028
US$34.36
Trending Discussion
Recently Updated Narratives
AN
ALT: Fast Track MASH Program Will Drive Future Upside Potential
Fair Value: US$15.45 79.5% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
Fair Value: US$28 88.7% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Altimmune, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -0.47
- -183,477.78%
- -253,002.78%
- 12.2%
About ALT
- Founded
- 1997
- Employees
- 57
- CEO
- WebsiteView website
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
